Abstract
Famciclovir has been shown to have potent and selective activity against herpesviruses. The possibility of a pharmacokinetic interaction between the anti-viral agent, famciclovir and allopurinol has been investigated in twelve healthy male volunteers following a single oral dose of famciclovir (500 mg) in the presence and absence of steady-state levels of allopurinol (300 mg). Similarly, the pharmacokinetic profiles of allopurinol and oxypurinol prior to and following a single dose of famciclovir were compared.
Mean values of Cmax, AUC and terminal-phase half-life for penciclovir following administration of famciclovir alone at 3.3 μg·ml-1, 8.8 μ·h·ml-1 and 2.1 h, respectively were unchanged by co-administration of allopurinol. Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 271·h-1, and when given with allopurinol 59.7% and 27.51·h-1, respectively. No evidence of accumulation of the inactive precursor to penciclovir, BRL 42359, was noted as a result of co-administration of the two drugs.
Mean steady-state Cmax, AUC and terminal-phase half-life values for allopurinol after co-administration of allopurinol with famciclovir also appeared unchanged from values obtained after dosing of allopurinol alone, at 2.12 μg·ml-1, 5.73 μg·h·ml-1 and 1.38h, respectively. Mean Cmax and AUC values of the active metabolite of allopurinol, oxypurinol were 11.2 μg·ml-1 and 96.0 μg·h·ml-1, respectively, and these were also unaltered by co-administration of famciclovir with allopurinol, with values of 10.6 μg/ml and 89.8 μg·h/ml, respectively.
In summary, no evidence of a pharmacokinetic interaction between allopurinol and famciclovir was observed when the two drugs were given concomitantly to healthy volunteers.
Similar content being viewed by others
References
Boyd MR, Bacon TH, Sutton D, Cole M (1987) Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 31: 1238–1242
Boyd MR, Bacon TH, Sutton D (1988) Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob Agents Chemother 32: 358–363
Pierce DM, Fowles SE, Fairless AJ, Prince WT (1994) The effect of food on the bioavailability of the antiherpes agent penciclovir from the prodrug, famciclovir. Br J Clin Pharmacol (in press)
Krenitsky TA, Spector T, Hall WW (1986) Xanthine oxidase from human liver: purification and characterisation. Arch Biochem Biophys 247: 108–119
Murrell GAC, Rapeport WG (1986) Clinical pharmacokinetics of allopurinol. Clin Pharmacol 11: 343–353
Fowles, SE, Pierce DM, Prince WT, Thomas D, Laroche J (1994) An investigation into the potential interaction between allopurinol and oral famciclovir in non-patient volunteers. Br J Clin Pharmacol (in press)
McMeekin JR, Fowles SE, Winton CF, Pierce DM (1992) Rapid high-performance liquid chromatography method for the analysis of the active antiherpes agent, penciclovir, and its precursor, BRL 42359 in human plasma and urine following administration of the oral prodrug, famciclovir. Anal Proc 29: 178–180
Kramer WG, Cheng SL (1980) Improvements to a high-performance chromatographic assay for allopurinol and oxypurinol in plasma. J Chromatog 181: 286
Allen GD (1990) MODFIT: a pharmacokinetics computer program. Biopharm Drug Dispos 11: 477–498
Yee KF (1986) Calculation of probabilities in rejecting bioequivalence. Biometrics 42: 961–965
Vere Hodge RA, Sutton D, Boyd MR, Harndon MR, Jarvest RL (1989) Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpes agent BRL 31923 [9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 33: 1765–1773
Harrel A, Wheeler SM, Pennick M, Clarke SE, Chenery RJ (1992) Evidence that famciclovir and its associated metabolites do not inhibit the 6-hydroxylation of testosterone in human liver microsomes. Drug Metab Dispos 21: 18–23
Raman GV, Sharman VL, Lee HA (1990) Azathiopurine and allopurinol: a potentially dangerous combination. J Intern Med 228: 69–71
Zimm S, Collins JM, ONeill BS, Chabner BA and Poplack GD (1983) Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol. Clin Pharm Ther 34: 810–817
Day RO, Miners J, Birkett DJ, Graham GG, Whithead A (1988) Relationship between plasma oxypurinol concentrations and xanthine oxidase in volunteers dosed with allopurinol. Br J Clin Pharmacol 26: 429–434
Day RO, Miners JO, Birkett DJ, Whithead A, Naidoo D, Hayes J, Savdie E (1988) Allopurinol dosage and selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 26: 423–428
Pratt SK, Fowles SE, Pierce D, Prince WT (1991) An investigation of the potential interaction between cimetidine and famciclovir in non-patient volunteers. Br J Clin Pharmacol 32: 656–657
Krenitsky TA, Neil SM, Elion GB, Hichings GH (1972) A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys 150: 585–599
Beedham C (1987) Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Progress Med Chem 24: 85–127
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fowles, S.E., Pratt, S.K., Laroche, J. et al. Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. Eur J Clin Pharmacol 46, 355–359 (1994). https://doi.org/10.1007/BF00194405
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00194405